文献速递神经肿瘤

CD44过表达与II/III级胶质瘤不良预后相关

Overexpression of CD44 is associated with a poor prognosis in grade II/III gliomas.
PubMed 文献 · J Neurooncol · 2019-09-10

该研究通过Oncomine数据库meta分析及Hokkaido大学医院112例II/III级胶质瘤患者qPCR检测,结合TCGA和CGGA数据库RNA-seq数据,发现CD44在胶质瘤组织中高表达,且高mRNA表达与较差总生存和无进展生存相关,多因素Cox回归证实CD44为独立预后因素。

要点

  • CD44在II/III级胶质瘤中高表达,且高表达提示预后不良。
  • CD44是II/III级胶质瘤的独立预后因素。
  • CD44可作为II/III级胶质瘤的预后生物标志物。

核心结论

  • CD44过表达与II/III级胶质瘤患者的不良预后相关。
  • CD44可作为II/III级胶质瘤的预后生物标志物。

研究设计与样本

  • 基于Oncomine数据库的meta分析评估CD44 RNA表达。
  • Hokkaido大学医院112例II/III级胶质瘤患者队列,qPCR检测CD44、CD44s和CD44v2-v10 mRNA表达。
  • 从TCGA和CGGA数据库获取II/III级胶质瘤患者的RNA-seq数据和临床数据。

主要发现

  • Oncomine数据库显示CD44在胶质瘤组织中较正常组织显著高表达。
  • 在HUH、TCGA和CGGA队列中,CD44高mRNA表达与较差总生存和无进展生存相关。
  • 多因素Cox回归分析证实CD44是II/III级胶质瘤患者的独立预后因素。

临床怎么用

  • 对II/III级胶质瘤患者可检测CD44表达以辅助预后评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Overexpression of CD44 has been detected in many types of tumor tissues. Moreover, CD44 is recognized as a cancer stem cell marker for many cancers. However, the prognostic value of CD44 for glioma patients has not yet been clarified. The authors tried to explore the impact of CD44 expression on grade II/III glioma patients. METHODS: To assess the RNA expression levels of CD44 in glioma tissues and normal brain tissues, meta-analyses were conducted in the online Oncomine database. The mRNA expression levels of CD44, CD44s, and CD44v2-v10 in 112 grade II/III glioma patients in Hokkaido University Hospital (HUH) were detected by qPCR. The RNA-seq data and clinical data of grade II/III glioma patients were obtained from The Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA) databases. RESULTS: Based on the Oncomine database, CD44 has significantly high expression in glioma tissues as compared with normal tissues. We explored the clinical relevance of CD44 mRNA expression based on the HUH cohorts, the TCGA cohorts, and the CGGA cohorts. In survival analysis, high mRNA expression of CD44 was correlated with poor overall survival and poor progression-free survival in grade II/III glioma patients. Multivariate Cox regression analyses confirmed CD44 as an independent prognostic factor for grade II/III glioma patients. CONCLUSIONS: The present study suggests that overexpression of CD44 is associated with a poor prognosis for grade II/III glioma patients. Moreover, our findings suggest that CD44 could serve as a prognostic biomarker in grade II/III glioma patients.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Hou C, Ishi Y, Motegi H, et al. Overexpression of CD44 is associated with a poor prognosis in grade II/III gliomas. J Neurooncol. 2019. PMID: 31506754. doi:10.1007/s11060-019-03288-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。